Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist

A method for treating a subject having chronic spontaneous urticaria (CSU) comprising administering to the subject an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R),

• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, respectively,
• wherein the subject is 12 years old to less than 18 years old,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject as an initial dose followed by one or more secondary doses, and
• wherein the antibody or antigen-binding fragment thereof is administered to the subject in a weight-dependent dosage;
• or
• a method for treating a subject having chronic spontaneous urticaria (CSU) comprising administering to the subject an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R),
• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, respectively,
• wherein the subject is 6 years old to less than 12 years old,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject as an initial dose followed by one or more secondary doses, and
• wherein the antibody or antigen-binding fragment thereof is administered to the subject in a weight-dependent dosage;
• or
• a method for treating a subject having chronic spontaneous urticaria (CSU) comprising administering to the subject an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R),
• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, respectively,
• wherein the subject is 2 years old to less than 6 years old,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject as an initial dose followed by one or more secondary doses, and
• wherein the antibody or antigen-binding fragment thereof is administered to the subject in a weight-dependent dosage.

A method for treating a subject having chronic spontaneous urticaria (CSU) comprising administering to the subject an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R),

• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, respectively,
• wherein the subject is the subject is 12 years old to less than 18 years old,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject as an initial dose followed by one or more secondary doses,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject in a weight dependent dosage, and
• wherein the subject was previously ineffectively treated with antihistamine therapy or anti-IgE antibody therapy, or
• a method for treating a subject having chronic spontaneous urticaria (CSU) comprising administering to the subject an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R),
• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, respectively,
• wherein the subject is the subject is 6 years old to less than 12 years old,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject as an initial dose followed by one or more secondary doses,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject in a weight dependent dosage, and
• wherein the subject was previously ineffectively treated with antihistamine therapy or anti-IgE antibody therapy;
• or
• a method for treating a subject having chronic spontaneous urticaria (CSU) comprising administering to the subject an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R),
• wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, respectively,
• wherein the subject is 2 years old to less than 6 years old,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject as an initial dose followed by one or more secondary doses,
• wherein the antibody or antigen-binding fragment thereof is administered to the subject in a weight dependent dosage, and
• wherein the subject was previously ineffectively treated with antihistamine therapy or anti-IgE antibody therapy.